{"id":"dulaglutide-injection","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dulaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, leading to reduced food intake and improved glycemic control. Additionally, it has cardiovascular benefits including blood pressure reduction and weight loss.","oneSentence":"Dulaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce glucagon release in response to elevated blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:05.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT07370922","phase":"PHASE2","title":"Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-22","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":80},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05478707","phase":"PHASE2","title":"Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes","status":"SUSPENDED","sponsor":"University of Virginia","startDate":"2023-10-05","conditions":"Diabetes Mellitus, Type 1, Endothelial Dysfunction","enrollment":47},{"nctId":"NCT06257966","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-17","conditions":"Type2 Diabetes Mellitus","enrollment":600},{"nctId":"NCT07156539","phase":"PHASE3","title":"A Phase 3 Study of HS-20094 in Patients With T2DM","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-09-30","conditions":"Type 2 Diabetes","enrollment":546},{"nctId":"NCT06324461","phase":"PHASE4","title":"GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-03-20","conditions":"Myocardial Injury","enrollment":372},{"nctId":"NCT06235086","phase":"PHASE3","title":"A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2024-04-08","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT05564039","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-30","conditions":"Type 2 Diabetes","enrollment":282},{"nctId":"NCT06901648","phase":"PHASE2","title":"A Study of HS-20094 in Patients With T2DM","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2024-02-06","conditions":"Type 2 Diabetes","enrollment":275},{"nctId":"NCT06148649","phase":"PHASE2","title":"Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Dongguan HEC Biopharmaceutical R&D Co., Ltd.","startDate":"2023-12-10","conditions":"Type 2 Diabetes","enrollment":234},{"nctId":"NCT05254418","phase":"PHASE2","title":"Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-03-15","conditions":"Chronic Kidney Diseases","enrollment":7},{"nctId":"NCT05659537","phase":"PHASE4","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-12-29","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT04862234","phase":"PHASE4","title":"Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients","status":"TERMINATED","sponsor":"Emory University","startDate":"2021-08-06","conditions":"Hyperglycemia Stress","enrollment":16},{"nctId":"NCT05516966","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2022-10-12","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03743025","phase":"PHASE4","title":"Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients","status":"TERMINATED","sponsor":"Emory University","startDate":"2019-03-08","conditions":"Stress Hyperglycemia","enrollment":28},{"nctId":"NCT06331286","phase":"NA","title":"The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-09-01","conditions":"Bipolar Disorder, Obesity, Cognition","enrollment":60},{"nctId":"NCT02759107","phase":"PHASE1","title":"A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05-11","conditions":"Healthy, Type 2 Diabetes Mellitus (T2DM)","enrollment":142},{"nctId":"NCT06182891","phase":"NA","title":"Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy","status":"COMPLETED","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2021-10-30","conditions":"Type 2 Diabetic Nephropathy","enrollment":300},{"nctId":"NCT04965506","phase":"PHASE2","title":"A Study of IBI362 in Chinese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-09-06","conditions":"Type 2 Diabetes","enrollment":252},{"nctId":"NCT05990374","phase":"NA","title":"Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-08-01","conditions":"Diabetes","enrollment":100},{"nctId":"NCT04867785","phase":"PHASE2","title":"A Study of LY3437943 in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-05-13","conditions":"Type 2 Diabetes","enrollment":281},{"nctId":"NCT04189848","phase":"PHASE4","title":"Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-12-03","conditions":"Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight","enrollment":104},{"nctId":"NCT03204396","phase":"PHASE2","title":"Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-06-26","conditions":"Glucagon-like Peptide-1, Smoking Cessation, Weight Change, Body","enrollment":256},{"nctId":"NCT04687514","phase":"PHASE2","title":"Effects of Glucagon-Like Peptide-1 Analogs on Sexuality","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-05-05","conditions":"Sexual Functioning","enrollment":26},{"nctId":"NCT05459285","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2022-05-31","conditions":"Type 2 Diabetes","enrollment":68},{"nctId":"NCT05348122","phase":"PHASE2","title":"A Study of TG103 Injection in Type 2 Diabetes Subjects","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2022-06-15","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT04374578","phase":"","title":"Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-05-08","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04829903","phase":"NA","title":"Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin","status":"COMPLETED","sponsor":"Corporacion Parc Tauli","startDate":"2020-01-02","conditions":"Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity","enrollment":116},{"nctId":"NCT03684642","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-09-26","conditions":"Type 2 Diabetes Mellitus","enrollment":908},{"nctId":"NCT04466904","phase":"PHASE1, PHASE2","title":"Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-09-12","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT03668470","phase":"PHASE2","title":"Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-01-31","conditions":"Adult Subjects With Type1Diabetes and Insulin Microsecretion","enrollment":45},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT03724981","phase":"PHASE4","title":"A Study Comparing the Dulaglutide Pen and the Semaglutide Pen","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-10-18","conditions":"Diabetes Mellitus, Type 2","enrollment":312},{"nctId":"NCT02770885","phase":"PHASE2","title":"Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-03","conditions":"Primary Polydipsia","enrollment":50},{"nctId":"NCT01621178","phase":"PHASE3","title":"A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes, Chronic Kidney Disease","enrollment":577},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT01644500","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":737},{"nctId":"NCT03648554","phase":"PHASE4","title":"Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2019-09-01","conditions":"Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis","enrollment":93},{"nctId":"NCT01001104","phase":"PHASE2","title":"A Study of LY2189265 in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT01558271","phase":"PHASE3","title":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-03","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00734474","phase":"PHASE2, PHASE3","title":"A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1202},{"nctId":"NCT01149421","phase":"PHASE2","title":"A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":755},{"nctId":"NCT01126580","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":807},{"nctId":"NCT00791479","phase":"PHASE2","title":"Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":167},{"nctId":"NCT00630825","phase":"PHASE2","title":"A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus Type 2","enrollment":262},{"nctId":"NCT01524770","phase":"PHASE1","title":"A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-03","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT01458210","phase":"PHASE1","title":"A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":22},{"nctId":"NCT01300260","phase":"PHASE1","title":"Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01215968","phase":"PHASE1","title":"A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-09","conditions":"Diabetes Mellitus, Type 2","enrollment":38},{"nctId":"NCT01253304","phase":"PHASE1","title":"A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT01436201","phase":"PHASE1","title":"A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["diet and exercise guidance treatment","Trulicity","TRULICITY®","Other hypoglycemic agents not including GLP-1 receptor agonists"],"phase":"marketed","status":"active","brandName":"dulaglutide injection","genericName":"dulaglutide injection","companyName":"First Affiliated Hospital of Zhejiang University","companyId":"first-affiliated-hospital-of-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dulaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce glucagon release in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}